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Highlights  
 
 Decreased levels of kynurenine was found in unipolar depression vs. healthy controls 
and no significant differences were found in tryptophan levels or kynurenine/tryptophan 
ratios in unipolar or bipolar disorder. 
 Substantial effect of heterogeneity in the results of studies reporting circulating levels of 
kynurenine metabolites  
 Kynurenine metabolites are likely to play a role in major depression but an exact 
etiological role in mood disorder seem complex and requires further research 
ABSTRACT  
Activation of the kynurenine pathway is one of the described mechanisms by which 
inflammation can induce depression. It involves multiple pathways including interference 
with the bioavailability of tryptophan central to the synthesis of the neurotransmitter 
serotonin. 
In this systematic review, we examine the relationship between kynurenine metabolites 
(kynurenine, kynurenic acid, tryptophan, quinolinic acid, the ratio of kynurenine and 
tryptophan) and mood disorders by conducting a meta-analysis.  
Fifty-six studies were identified, 21 met inclusion criteria and 14 were deemed suitable (9 
investigating unipolar depression and 5 bipolar disorder).  
We found decreased levels of kynurenine in unipolar major depression vs. healthy 
controls but studies were significantly heterogeneous in nature. No significant 
differences were found in tryptophan levels or kynurenine/tryptophan ratios. 
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Kynurenine metabolites are likely to play a role in major depression but an exact 
etiological role in mood disorder seem complex and requires further research.  
 
Keywords: Kynurenine, Mood disorder, Depression, Bipolar disorder, tryptophan, inflammation, 
quinolinic acid  
 
INTRODUCTION 
Major depressive disorder (MDD) and bipolar disorder (BD) are leading causes of mental 
disorders worldwide (Whiteford et al., 2013). They are a major public health concern due 
to their chronicity, risk of suicide and high co-morbidity with other disabling diseases such 
as diabetes and cardiovascular diseases (Angst et al., 2013; Barth et al., 2004; Fornaro 
et al., 2017; Greenberg et al., 2015; Hesdorffer et al., 2000; Knol et al., 2006; Simon, 
2003). The underlying pathophysiology of these disorders is complex, possibly involving 
multiple biological systems including immune, endocrine, and metabolic processes 
impacting the functional and structural aspects of the brain. Understanding this 
pathophysiology is critical for the development of new treatment and effective relapse 
prevention strategies.  
 
A consistent body of evidence from both preclinical and clinical studies shows that 
inflammation in both periphery and the central nervous system plays a role in the 
pathophysiology of mood disorders. Elevated peripheral pro-inflammatory markers have 
been associated with depression and bipolar disorders (Miller et al., 2009; Strawbridge et 
al., 2015). Further evidence originates from the clinical observation that one-third of 
AC
CE
PT
ED
 M
AN
US
CR
IPT
4 
patients treated for cancer or hepatitis C with the pro-inflammatory cytokine interferon-
alpha (IFNα) develop an MDD (Widner et al., 2000) whereas anti-inflammatory agents 
such as cyclooxygenase-2 (COX-2) inhibitors and N-acetyl cysteine could contribute to 
alleviating depressive symptoms (Müller, 2010). In addition, the prevalence of MDD is 
higher in patients with chronic medical conditions such as rheumatoid arthritis and type 2 
diabetes which are often characterized by low-grade chronic inflammation (Katon et al., 
2010).  
 
Communication between the immune system and the brain takes place through multiple 
pathways, including neural afferents and circulating immune mediators which activate 
brain endothelial and innate immune cells (perivascular and meningeal macrophages, 
microglia) (Dantzer et al., 2008). Activated microglia release pro-inflammatory cytokines 
such as IL-1, IL-6, TNF, and prostaglandins (Perry et al., 2010). Dysregulation of this 
reciprocal interaction between the nervous and immune systems may lead to neuronal 
damage or neurodegeneration (Miller et al., 2009). 
 
Serotonin is biochemically derived from tryptophan (TRP). Decreased brain 
serotoninergic neurotransmission forms the basis of the serotonin hypothesis of 
depression (Coppen, 1968). Activation of the kynurenine pathway (KP) is one of the 
potential mechanisms by which inflammation can induce depression by interfering with 
the metabolism of TRP (Dantzer et al., 2011; Oxenkrug, 2010). Two major enzymatic 
pathways metabolize TRP. One pathway utilizes the liver enzyme tryptophan 2, 3 
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dioxygenase (TDO2) of which the activity is regulated by glucocorticoids. The other 
pathway is regulated by the ubiquitous indoleamine 2, 3 dioxygenase (IDO1) enzyme. 
IDO1 is activated by proinflammatory cytokines especially interferon gamma (IFNγ). 
Downstream of IDO1, two separate metabolic pathways transform kynurenine (KYN), the 
main metabolite of TRP, to the neuroprotective kynurenic acid (KYNA) in astrocytes or 
the neurotoxic 3-hydroxykynurenine (3-HK) and quinolinic acid (QUIN) in microglia (Müller 
and Schwarz, 2008; Schwarcz et al., 2012). This latter pathway is regulated by activation 
of microglial kynurenine mono-oxygenase (KMO). KYN/TRP ratio provides a measure of 
peripheral tryptophan breakdown and is used as an index of IDO1 activity when observed 
with other immune activation markers such as neopterin (Dantzer et al., 2011).  
 
Current pathogenic models suggest that elevated pro-inflammatory cytokines activate 
IDO1 and KMO resulting in increased susceptibility to MDD (Campbell et al., 2014) by 
switching the kynurenine metabolites balance towards neurotoxicity (Müller and Schwarz, 
2008; Myint and Kim, 2003). Moreover, preclinical studies have demonstrated that 
inflammation-induced depression is mediated by increased brain levels of QUIN 
activating NMDA receptors (Walker et al., 2013). This is in agreement with the therapeutic 
role of ketamine in the treatment of MDD and the central role played by astrocytes and 
microglia in glutamine/glutamate dysregulation (Arnone et al., 2015), potentially 
enhancing neurotoxicity of quinolinic acid (Dantzer and Walker, 2014). Thus, KYNA/QA 
ratio is proposed as putative neuroprotection index in that decreases in the ratio may 
contribute to inflammation-induced pathology (Savitz et al., 2015a; Savitz et al., 2015b).  
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Results from prospective cohort studies in which patients with cancer or hepatitis C virus 
infection are administered IFN-alpha and mood symptoms are assessed longitudinally 
together with KP metabolites reveal consistent increases in plasma KYN metabolites 
associated with symptoms of depression and support the ‘inflammatory hypothesis’ for 
depression pathogenesis (Baranyi et al., 2015; Bonaccorso et al., 2002; Capuron et al., 
2003). Activation of KP is associated with decreased TRP, increased KYN, increased 
KYN/TRP ratio and possibly decrease in the neuroprotective index KYNA/QA ratio. A 
meta-analysis of studies measuring plasma tryptophan levels in patients with MDD 
showed reduced plasma TRP levels (Ogawa et al., 2014) (Ogawa et al 2014). However, 
the results from studies measuring peripheral blood-based KP metabolites in mood 
disorders are not always consistent, as increases, decreases or no changes in KP 
metabolites have been reported.  
 
In this review, we examine the relationship between activation of the kynurenine pathway 
and mood disorders by systematically reviewing the literature and by running a meta-
analysis. We specifically included studies that investigated tryptophan and kynurenine 
metabolites (tryptophan, kynurenine, kynurenic acid, quinolinic acid, ratio of kynurenine 
to tryptophan) in patients with MDD or BD. We predicted that decreased TRP, increased 
KYN, increased KYN/TRP ratio and decreased KYNA/QA ratio would be associated with 
MDD and BD. 
 
METHODS 
Search strategy 
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The review process adhered to the principles of the PRISMA-Statement (Liberati et al., 
2009; Moher et al., 2009; Shamseer et al., 2015). We intended to study the relationship 
between activation of the kynurenine pathway and mood disorders. Eligibility criteria 
included: 1) English language articles, 2) Studies published in peer-reviewed journals, 
and 3) Matched case-control studies comparing patients with mood disorders (unipolar 
and bipolar disorders) with healthy controls and measuring the circulating levels of 
kynurenine pathway metabolites reported as means and standard deviation. We also 
considered longitudinal studies which provided a baseline evaluation. As a secondary 
analysis, we considered the possibility of measuring longitudinal changes in response to 
pharmacological or psychological treatment. 
 
We excluded studies carried out in physically ill patients with mood symptoms, e.g., HIV 
or Hepatitis C infected individuals. We developed a protocol to review study eligibility, 
information sources, and data elements for abstraction (available upon request). Ovid 
Medline, Elsevier EMBASE, Cochrane library, and Ovid PsycINFO were systematically 
researched from inception to June 2017. The search terms included – “Kynurenine” 
[Mesh] OR "Kynurenine" [tw] OR "Quinolinic Acid" [Mesh] OR "Quinolinic Acid" [tw] OR 
"picolinic acid" [Supplementary Concept] OR "picolinic acid" [tw] OR "3-
Hydroxyanthranilic Acid" [Mesh] OR "3-Hydroxyanthranilic Acid" [tw] OR "kynurenine 
metabolites" [tw] OR "kynurenine metabolite" [tw] AND "Affect" [Mesh] OR "Affect" [tw] 
OR "Mood Disorders" [Mesh] OR "Mood Disorders" [tw] OR "mood" [tw] OR "mood 
symptoms" [tw]. The detailed search strategy is provided as online Appendix A. Study 
eligibility was assessed following the criteria are shown in the flowchart in Figure 1. Two 
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trained reviewers (SS, HS) independently reviewed the unduplicated records retrieved 
from the search to assess eligibility and resolved uncertainty by consensus (SS, HS, and 
DA). Basic demographic information and clinical variables were systematically extracted 
including all available levels of metabolites.  
 
 
 
Quality assessment, Data synthesis, and analysis 
Study quality assessment and scoring was carried out by using the ‘Study Quality Form’ 
from the ‘Guide to Community Preventive Services’ (Zaza et al., 2000) and varied based 
on the ‘number of limitations' from ‘good’ (0-1) to ‘fair’ (2-4) and ‘limited’ (≥ 5).   
 
Meta-analysis was conducted using STATA 9.0 (Stata Corp, College Station, Texas) 
supplemented by ‘Metan’ software downloadable from the Centre for Statistics in 
Medicine, Oxford, UK as previously described (Arnone et al., 2009; Arnone et al., 2012; 
Lavagnino et al., 2016; Selvaraj et al., 2014). Standardised mean differences were 
calculated using Cohen’s d statistic. The presence of heterogeneity was tested using the 
Q-test. Its magnitude was estimated using I2, which can be interpreted as the proportion 
of effect size variance due to heterogeneity (Higgins et al., 2003). If the Q-test was 
significant, Galbraith plot served to identify studies contributing to heterogeneity. We 
explored heterogeneity with meta-regression by using all the available confounders 
including a year of publication, mean age, the percentage of depressed men, and illness 
severity for both symptoms of depression and elation whenever possible. Publication bias 
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was examined using the Egger’s test (Egger et al., 1997) with a significance level of p < 
0.05. 
 
RESULTS 
Study selection 
The initial database search identified 1,456 eligible studies, 56 survived the initial 
suitability assessment and additional hand search identified 2 more studies each in MDD 
and BD respectively. Twenty-one were included in the meta-analysis (14 investigating 
MDD and 7 BD) (Figure 1: Flow diagram). Table 1 and 2 summarizes the details of the 
studies included in the meta-analysis and the Supplementary Table describes details of 
the selection process and quality assessment.  
 
MDD in comparison with healthy controls 
Fourteen studies were identified and eleven met inclusion criteria (Baranyi et al., 2017; 
Bradley et al., 2015; Dahl et al., 2015; Krause et al., 2017; Meier et al., 2016; Myint et al., 
2013; Myint et al., 2007b; Neupane et al., 2015; Quak et al., 2014; Savitz et al., 2015b; 
Sorgdrager et al., 2017; Sublette et al., 2011; Umehara et al., 2017; Wood et al., 1978) 
(Table 1) having excluded the study by Myint and colleagues, 2013  (Myint et al., 2013) 
because cases and controls were not fully matched at baseline, Myint and colleagues, 
2007 (Myint et al., 2007b) which enrolled patients with BD, and Neupane and colleagues 
(Neupane et al., 2015) which included participants with alcohol-related disorders. The 
studies by Meier and colleagues (2015) and by Savitz and colleagues (2015) (Savitz et 
al., 2015b) contained the same participants and were included in separate analyses. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
10 
Quak et al. (Quak et al., 2014) and Sorgdrager et al. (Sorgdrager et al., 2017) shared 
study participants and the study with the largest sample size (Quak et al., 2014) was 
included (supplementary data were made available by the authors). The majority of the 
studies included unmedicated patients aside Quak and others (Quak et al., 2014), Bradley 
and others (Bradley et al., 2015) and Baranyi and colleagues (Baranyi et al., 2017). 
 
a) Circulating levels of kynurenine 
Analysis of the nine studies available (Baranyi et al., 2017; Bradley et al., 2015; Dahl et 
al., 2015; Krause et al., 2017; Meier et al., 2016; Quak et al., 2014; Sublette et al., 2011; 
Umehara et al., 2017; Wood et al., 1978) showed a significant reduction in kynurenine in 
MDD vs. healthy controls with an effect size of -0.21 (CI: -0.39, -0.03) (Figure 2a). 
Significant heterogeneity (p=0.027) was systematically explored with meta-regression 
analyses. None of the available variables extracted from the studies proved to explain the 
variance of the effect size (year of publication, mean age, %men, illness severity, number 
of medicated individuals, all ps>0.05). There was no evidence of publication bias 
(p=0.47). 
 
b) Circulating levels of tryptophan  
Six studies were included in this analysis (Bradley et al., 2015; Dahl et al., 2015; Meier et 
al., 2016; Quak et al., 2014; Sublette et al., 2011; Wood et al., 1978) which showed a 
non-significant reduction in levels of TRP in patients with MDD. The effect size was -0.20 
(CI: -048, 0.07). There was significant heterogeneity (p=0.001). Meta-regressions 
indicated that prescribed medication influenced the effect size (Coef: 0.0007, Z=3.02, 
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p=0.003) as well as % men (Coef: -0.01, Z=-2.49, p=0.013), and year of publication (Coef: 
-0.17, Z=-3.27, p=0.001), whereas severity trended to significance (Coef: -0.18, Z=-1.94, 
p=0.053) and mean age was not significant (p=0.57). There was no evidence of 
publication bias (p=0.25). 
 
 
 
c) Kynurenine/tryptophan ratio 
Six studies were included in this analysis (Baranyi et al., 2017; Bradley et al., 2015; Dahl 
et al., 2015; Meier et al., 2016; Quak et al., 2014; Sublette et al., 2011) and indicated a 
trend towards an increase in the kynurenine/tryptophan ratio in MDD with an effect size 
of 0.18 (CI: -0.06, 0.42). This analysis was characterized by high level of heterogeneity 
(p=0.006). The presence of publication bias (p=0.018) indicated that results from these 
studies are not necessarily generalizable. Exploration of heterogeneity indicated that the 
effect size correlated with increasing number of medicated patients (coeff: -0.0002, Z=-
3.62, p<0.001), whereas a year of publication, mean age of the depressed group, % of 
men and severity did not affect the effect size (all Ps>0.05). 
 
d) Kynurenic acid/quinolinic acid ratio 
There were no sufficient studies in MDD to carry out this analysis. 
 
Bipolar disorder in comparison with healthy controls 
Seven studies were identified of which five studies were included (Myint et al., 2007a; 
Platzer et al., 2017; Poletti et al., 2016; Reininghaus et al., 2014; Savitz et al., 2015a) 
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(Table 2) having excluded the post-mortem study by Miller and colleagues (2008) and the 
study by Birner and colleagues (Birner et al., 2017) overlapping with Platzer and 
colleagues (Platzer et al., 2017) already included in the same analyses. Overlapping data 
from Reininghaus and colleagues (2014) and Platzer et al. (2017) were considered in 
separate sub-analyses. All patients were medicated aside the study by Myint and others 
(Myint et al., 2007a) resulting in very little variance for a meaningful analysis. 
 
a) Circulating levels of kynurenine  
Four studies were included in this analysis (Myint et al., 2007a; Platzer et al., 2017; Poletti 
et al., 2016; Savitz et al., 2015a) which showed a non-significant marginal decrease in 
levels of kynurenine with an effect size of -0.42 (CI: -1.18, 0.34). There was evidence of 
a high level of heterogeneity (p<0.001) in the absence of publication bias (p=0.51). 
Exploration of heterogeneity with meta-regression analyses based on the available 
variables showed that a higher percentage of men (Coeff: 3.75, Z=6.23, p<0.001) 
positively correlated with the effect size, but not the year of publication, mean age and 
severity of illness (all ps>0.05). 
 
b) Circulating levels of tryptophan 
Four studies were included in this analysis (Myint et al., 2007a; Platzer et al., 2017; Poletti 
et al., 2016; Savitz et al., 2015a) which showed a non-significant tendency to a reduction 
in levels of TRP in patients with BD. The effect size was -1.15 (CI: -2.43, 0.1). There was 
evidence of significant heterogeneity (p<0.001) in the absence of publication bias (p=0.3). 
Meta-regressions indicated that the effect size positively correlated with increasing 
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percentage of men (Coeff: 6.93, Z=3.04, p=0.002). Year of publication, mean age of the 
patients, and severity of illness did not affect the effect size (ps>0.05). 
 
c) Kynurenine/tryptophan ratio 
Four studies were included in this analysis (Myint et al., 2007a; Poletti et al., 2016; 
Reininghaus et al., 2014; Savitz et al., 2015a) which indicated a non-significant tendency 
to an increased ratio 0.24 (CI: -0.10, 0.59) with significant heterogeneity (P=0.025) and 
no evidence of publication bias (p=0.35). Meta-regressions indicated that the effect size 
positively correlated with increasing age (Coeff: 0.056, Z=2.62, p=0.009). Year of 
publication, %men, and severity of illness did not affect the effect size (ps>0.05). 
 
d) Kynurenic acid/quinolinic acid ratio 
There were no sufficient studies in BD to carry out this analysis. 
 
Longitudinal studies evaluating the effect of therapeutic interventions and clinical 
outcome on kynurenine pathways 
There were only two studies evaluating the effect of pharmacological interventions on 
kynurenine pathways in patients with MDD (Krause et al., 2012; Wood et al., 1978), but 
none in BD meeting our inclusion criteria. Hence it was not possible to conduct meta-
analyses. Wood and colleagues (Wood et al., 1978) found that clinical outcome could not 
be accurately predicted by measurements of plasma kynurenine levels. They also 
reported that amitriptyline did not significantly increase plasma kynurenine concentration 
contrary to lithium and mianserin. Krause and others reported that higher 
kynurenine/tryptophan ratio at baseline predicted remission in reboxetine-treated patients 
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with MDD with or without adjuvant treatment with the cyclooxygenase-2 inhibitor 
celecoxib. Remitters were also characterized by lower kynurenic acid/kynurenine and 
quinolinic acid/kynurenine ratios. Authors proposed that lower downstream kynurenine 
metabolites formation were likely to be predictive of better outcome (Krause et al., 2012). 
 
 
DISCUSSION 
In this manuscript, we set out to review the range of kynurenine metabolites variations in 
MDD/BD in comparison with healthy controls by selecting the most robust evidence 
available in the literature to generate summary effect sizes. Our results indicate that 
although kynurenine metabolites show variations in affected individuals, these changes 
are of a small magnitude and reach significance in the analysis of kynurenine metabolites 
in unipolar major depression. Based on the data analyzed, alterations of the balance 
between neuroprotective and neurotoxic kynurenine metabolites could still play a 
pathogenic role in subgroups of patients with mood disorders. The direction of 
changes in kynurenine metabolites which indicates a reduction in major 
depression vs. healthy controls rather than an increase as we anticipated suggests 
that major depression in chronic inflammatory conditions may etiologically differ 
from other depressive disorders. 
 
In both MDD and BD the high level of heterogeneity suggests that a number of 
confounders and clinical variables are likely to contribute to the effect size so that 
variables such as year of publication, age of participants, sex, and illness severity for both 
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symptoms of depression and mania appear to influence variations in the effect size. 
Furthermore, in the case of kynurenine/tryptophan ratio in MDD, the presence of 
publication bias seems to suggest that studies might be of a too small magnitude to detect 
meaningful differences without incurring into type I/II error.  
 
There were differences in design across all the studies reviewed. For example, a large 
number of studies were observational and presented naturalistic uncontrolled data. Case-
control studies, which represent the main source of this review, did not offer any 
information regarding the temporal and/or directional relationship between mood 
disorders and kynurenine metabolites variations. The results from the only two 
prospective cohort studies that were included in the present meta-analysis provided 
insufficient data to allow conclusive statements about the generalizability of the results.  
Other putative factors shown to affect levels of kynurenine metabolites include 
antidepressants and other treatments like electroconvulsive therapy (Cervenka et al., 
2017). However, the variations in the effect size of reduction of kynurenine levels seen in 
MDD patients vs. controls was not explained by the antidepressant medication status in 
our analyses.  
 
Other potential limitations include the effects of weight and obesity, physical activity, use 
of tobacco and other addictive drugs. TDO and IDO are two major enzymatic pathways 
that metabolize TRP with the TDO’s activity regulated by glucocorticoids and IDO 
activated by proinflammatory cytokines such as IFNγ. Effect of dietary 
modifications, body weight, and physical activity can affect tryptophan levels and 
therefore kynurenine pathway and its metabolites both in patients with mood 
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disorders and in healthy controls (Cervenka et al., 2017; Strasser, 2017). However, 
these factors are not controlled in all studies. For example, Reininghaus et al report 
increased KYN and KYN/TRY ratio levels in overweight bipolar disorder patients. 
Future studies should take these factors into consideration when evaluating KP 
pathway in mood disorders. 
 
The question also remains whether peripheral measurements are the optimal approach 
to evaluate kynurenine metabolites and whether effectively reflect brain concentrations. 
Raison et al. 2010 (Raison et al., 2010) is the only study that evaluated the effect of IFN-
alpha/ribavirin therapy on both plasma and cerebrospinal fluid (CSF) levels of TRP, KYN 
and QUIN as well as the KYN/TRP ratio in HCV patients (n=16). IFN-alpha administration 
increased KYN in peripheral blood and KYN, QUIN and KYNA in the CSF after ~12 weeks 
compared to control patients. CSF KYN and QUIN correlated with the severity of 
depressive symptoms and, in addition, plasma KYN and QUIN concentrations correlated 
with the CSF KYN and QUIN concentrations.  Thus, Raison et al. study, though with 
limited sample size, provides evidence that changes in peripheral KYN metabolism are 
linked to central nervous system cytokine responses in this specific IFN-alpha-induced 
depression. Future prospective studies including both peripheral and CSF measures of 
KP metabolites in mood disorders are required to better define if peripheral and CSF 
levels are indeed correlated and if they are relevant to the course of illness and treatment.  
 
It is also unknown if any specific kynurenine metabolite could efficiently reflect symptom 
changes in mood disorders. It has been suggested that downstream metabolites such as 
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KYNA and/or QUIN could possibly allow a more refined understanding of the underlying 
mechanisms of mood regulation in view of their interaction with inflammatory responses 
(Myint, 2012). However, this hypothesis remains to be tested as it is not possible based 
on the results presented here to comment on whether alterations in kynurenine pathways 
are a consequence of inflammation or are driven by alterations in cortisol levels possibly 
modulated by susceptibility to stress (Dantzer et al., 2011).  
 
In addition to depression, inflammation has been linked to suicidal risk. When plasma 
KYN and TRP were assayed in patients with MDD with and without a history of suicide 
attempts, KYN and K/T ratio were significantly higher in MDD patients with suicide attempt 
while higher KYN, K/T ratio predicted suicide attempt (Sublette et al., 2011). 
Cerebrospinal fluid levels of QUIN and KYNA measured in suicide attempters and 
controls showed that QUIN was significantly elevated in suicidal patients and QUIN 
correlated with suicide intent scale (Erhardt et al., 2013). Together these findings suggest 
that the pharmacologic manipulation of KYN levels might reduce suicide risk. 
 
High KYN levels were associated with increased immune activation, while pre and post-
treatment KYN levels significantly predicted changes in depression, suggesting that 
heightened KP activation may contribute to depressive symptoms in patients treated for 
cancer. Findings from a pancreatic cancer study yielded similar results, reflecting tumor-
induced immunomodulation in the pathophysiology of depression (Botwinick et al., 2014). 
However, patients with renal cell carcinoma (Van Gool et al., 2008), receiving IFN-α 
showed an increase in K/T ratio during the treatment, but no correlation was observed 
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between psychiatric symptoms and KP metabolites. Thus, KP pathway measures 
associated with immune activation do not always relate to mood changes. 
 
Limitations of this meta-analysis include the small number of studies included, the nature 
of case-control studies and absence of randomization, the occurrence of study bias so 
that studies were generally similar with relatively small sample sizes resulting in relatively 
low statistical power and the very high level of between studies heterogeneity. There are 
limitations in the estimation of effect sizes based on the inverse-variance methodology 
we used in this work especially in relation to the variance introduced by confounders. 
Hence, we explored all the possible causes of heterogeneity by using meta-regression 
analyses based on the variables we could consistently extract from the studies. Other 
approaches such as the Mantel-Haenszel methods offer advantages over the method we 
used here although constrained in the presence of several confounders and the relatively 
small sample sizes characterizing the studies included in this review (Tripepi et al., 2010). 
Mood disorders are often heterogeneous clinical presentations which limit our 
ability to generalize the results from this meta-analysis largely based on studies 
which did not specifically include linear effects. This is particularly relevant in view 
of the high levels of heterogeneity noted in the analyses, the low power of meta-
regressions (Arnone et al., 2012) and the discrepancies in the confounders 
reported in the original studies.  Future work would benefit from focusing on 
kynurenine changes linked to between-subject heterogeneity to more specifically 
improve precision and generalizability of the results. 
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In conclusion, the main finding of our work suggests a reduction in kynurenine metabolites 
in major depression vs. healthy controls. The direction of the change contravenes the 
postulated theoretical increase based on findings of low mood in chronic and 
inflammatory diseases and would require replication and exploration in future 
studies with particular attention to linear effects. If confirmed, this result suggests 
different etiologies for mood dysregulation. Our findings support a role for kynurenine 
metabolites variations in the pathogenesis of mood disorders, although it does not allow 
definitive conclusions regarding its role in mood disorders due to the complex interaction 
among epidemiological and clinical factors. This finding is important in guiding further 
research which would benefit from larger studies preferably comparing kynurenine 
metabolites in individual experiencing mood disorders with and without inflammatory 
conditions in comparison with healthy controls. Furthermore, systematic measurements 
of inflammatory markers, cortisol levels, stress responses and a comprehensive 
exploration of clinical and epidemiological variables would allow to evaluate the impact of 
these potential variables on kynurenine metabolites measurements and increase the 
precision of the findings.  
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Figure 1: Study flow for the systematic review – Kynurenine Pathway and Mood Disorders  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Meta-analysis output (funnel plot) in the unipolar major depression of 
circulating levels of kynurenine metabolites 
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Table 1: Kynurenine Pathway metabolites in patients with major depressive disorder 
compared to healthy controls 
Table 1: Kynurenine Pathway metabolites in patients with major depressive disorder 
compared to healthy controls  
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K/T in 
all 
subject
s and 
in 
subject
s with 
current 
MDD 
 
 
 
Yes  
 
(N=4
62) 
Brad
ley 
K, 
201
5 
50 
(35/
15) 
15
.9  
(2.
1) 
22 
(9/1
3) 
16 
(2.6) 
898.
9 
(68
5.8) 
ng/
ml 
374
.2 
(13
8.2) 
ng/
ml 
0.5
8 
(0.
34) 
 
 
NR 
982
.9 
(40
6.3
) 
ng/
ml 
408.7
(148.
1) 
ng/ml 
0.4
9 
(0.
27) 
NR 
No 
differe
nce in 
KYN,  
TRY 
and 
KYN/
TRY 
NR 
 
Yes 
(n=1
7) 
 
Dahl 
J, 
201
5 
50 
(12/
38) 
40 
(1
2.
0) 
34 
(15/
19) 
38.3 
(13.
9) 
56.6 
(11.
4) 
M/
l 
2.0 
(0.6
) 
0.0
4 
(0.
03-
0.0
38) 
 
 
 
 
 
 
 
 
54.
6 
(12
.4) 
2.2 
(0.82) 
0.0
4 
(0.
02
9-
0.0
4) 
 
 
No 
differe
nce in 
KYN,  
TRY, 
KYN/
TRY 
and 
KYN/
QA 
ratios 
K/T 
ratio 
positiv
ely 
correla
ted 
with 
the 
plasma 
conc. 
of 
cytoki
nes in 
HC but 
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Aut
hor, 
Yea
r 
Depresse
d patients 
Controls Depressed patients Controls 
 
Main 
findin
gs 
Inflam
mator
y 
maker
s 
 
Anti-
depr
essan
t 
Medi
catio
n  
 
 
N 
(M/
F) 
A
ge 
m
ea
n 
(S
D) 
N 
(M/
F) 
Age 
mea
n 
(SD) 
TR
P 
mea
n 
(SD
) 
KY
N 
me
an 
(SD
) 
K/
T 
Ra
tio 
me
an 
(S
D) 
 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
TR
P 
me
an 
(S
D) 
KYN 
mean 
(SD) 
K/
T 
Ra
tio 
me
an 
(S
D) 
 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
  
 
not in 
MDD 
patient
s. 
Mei
er T, 
201
5 
73 
(16/
57) 
34
.2 
(9.
3) 
91 
(36/
55) 
31.6 
(9.3) 
 
54.4 
(11.
4) 
M 
 
1.9
0 
(0.5
) 
 
0.0
4 
(0.
01) 
0.11 
(0.04) 
60.
4 
(17
.4) 
 
1.95 ± 
0.48 
 
0.0
3 
(0.
01) 
0.12 
(0.04) 
 
 
 
 
No 
differe
nce in 
KYN,  
TRY 
and 
KYN/
TRY 
 
KYN/
QA 
ratios 
reducti
ons 
not 
presen
t after 
correct
ions 
log 
normal
ized 
CRP 
correla
ted 
with 
TRY, 
KYN/
TRY 
and 
KYN/
QA 
ration 
in both 
groups 
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Aut
hor, 
Yea
r 
Depresse
d patients 
Controls Depressed patients Controls 
 
Main 
findin
gs 
Inflam
mator
y 
maker
s 
 
Anti-
depr
essan
t 
Medi
catio
n  
 
 
N 
(M/
F) 
A
ge 
m
ea
n 
(S
D) 
N 
(M/
F) 
Age 
mea
n 
(SD) 
TR
P 
mea
n 
(SD
) 
KY
N 
me
an 
(SD
) 
K/
T 
Ra
tio 
me
an 
(S
D) 
 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
TR
P 
me
an 
(S
D) 
KYN 
mean 
(SD) 
K/
T 
Ra
tio 
me
an 
(S
D) 
 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
  
 
Bara
nyi, 
201
7 
71 
(47/
24) 
49
.2  
(1
1.
4) 
48 
(31/
17) 
46.1 
(18.
3) 
 
 
60.1 
(10.
9) 
m
ol/L 
 
 
 
 
 
2.4 
(0.6
2) 
m
ol/L 
 
 
 
 
0.0
4 
(0.
01) 
 
NR 
 
 
 
67.
7 
(9.
5) 
m
ol/
L 
 
 
2.5 
(0.62) 
mol/
L 
 
0.0
4 
(0.
01) 
NR 
 
 
 
 
No 
differe
nce in 
KYN, 
KYN/
TRY 
and 
QA 
 
Decrea
sed 
TRY 
and 
KYN
A in 
patient
s 
 
 
NR 
 
 
 
 
 
 
 
 
 
Yes 
(n=5
9) 
 
 
 
Kra
use, 
201
7 
32 
(16/
16) 
44
.6 
(1
1.
6) 
20 
(15/
5) 
40 
(10.
4) 
NR 
1.7
8 
(0.3
5) 
NR 
0.17 
(0.05) 
*Qui
n/KY
N 
ratio 
 
NR 
2.04 
(0.35) 
NR 
 
0.14 
(0.03) 
*Qui
n/KY
N 
ratio 
 
 
Decrea
sed 
KYN 
 
Increa
sed 
*Quin/
KYN 
ratio 
 
 
NR 
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Aut
hor, 
Yea
r 
Depresse
d patients 
Controls Depressed patients Controls 
 
Main 
findin
gs 
Inflam
mator
y 
maker
s 
 
Anti-
depr
essan
t 
Medi
catio
n  
 
 
N 
(M/
F) 
A
ge 
m
ea
n 
(S
D) 
N 
(M/
F) 
Age 
mea
n 
(SD) 
TR
P 
mea
n 
(SD
) 
KY
N 
me
an 
(SD
) 
K/
T 
Ra
tio 
me
an 
(S
D) 
 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
TR
P 
me
an 
(S
D) 
KYN 
mean 
(SD) 
K/
T 
Ra
tio 
me
an 
(S
D) 
 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
  
 
Ume
hara
, 
201
7 
33 
(10/
23) 
47
.1 
(1
3.
2) 
33 
(10/
23) 
46.5 
(10.
1) 
NR 
0.0
004 
(0.0
001
) 
0.0
26 
(0.
00
1) 
NR NR 
0.000
5 
(0.00
01) 
0.0
31 
(0.
00
1) 
NR 
Decrea
sed 
KYN 
and no 
differe
nce in 
KYN/
TRY 
ratio 
 
KYN 
levels 
normal
ized 
after 
antide
pressa
nt 
treatm
ent 
NR 
 
 
 
 
 
 
 
 
 
 
No 
 
 
NR- Not Reported; NS – Non significant 
 
TRP - Tryptophan; KYN - Kynurenine; K/T ratio – Kynurenine/Tryptophan ratio; KYNA - Kynureninc Acid; QA - Quinolinic 
acid 
 
MDD – Major Depressive Disorder; CRP – c-reactive protein; IL-6 – Interleukin-6 
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Table 2: Kynurenine Pathway metabolites in patients with bipolar disorder compared to healthy 
controls 
(insert) 
Table 2: Kynurenine Pathway metabolites in patients with bipolar disorder compared to 
healthy controls  
 
Auth
or, 
Year 
Bipolar 
patients 
Controls Bipolar patients Control patients 
Main 
findings 
Inflam
mator
y 
maker
s 
N 
(M
/F) 
Ag
e 
m
ea
n 
(S
D) 
N 
Ag
e 
m
ea
n 
(S
D) 
TRP 
mea
n 
(SD) 
KY
N 
mea
n 
(SD) 
K/T 
ratio 
mean 
(SD) 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
TRP 
mea
n 
(SD) 
KY
N 
mea
n 
(SD) 
K/T 
ratio 
mean 
(SD) 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
Myint 
2007a 
39 
(15
/24
) 
37
.6 
(1
1.
6) 
80 
(40
/40
) 
39
.1  
(8.
8) 
61.0 
(15.
9) 
(μm
ol/l) 
1.72
±0.6
5 
(μm
ol/l) 
0.028
±0.01
1 
 
 
 
 
NR 
70.6
±12.
7 
(μm
ol/l) 
1.88
±0.4
6 
(μm
ol/l) 
0.027
±0.00
7 
 
 
 
 
NR 
 
 
 
Bipolar 
mania 
 
Decreased 
T
R
P 
i
n 
p
a
t
i
e
n
t
s 
w
i
t
h 
m
a
n
i
a 
No 
d
i
f
f
e
r
e
n
c
NR 
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Auth
or, 
Year 
Bipolar 
patients 
Controls Bipolar patients Control patients 
Main 
findings 
Inflam
mator
y 
maker
s 
N 
(M
/F) 
Ag
e 
m
ea
n 
(S
D) 
N 
Ag
e 
m
ea
n 
(S
D) 
TRP 
mea
n 
(SD) 
KY
N 
mea
n 
(SD) 
K/T 
ratio 
mean 
(SD) 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
TRP 
mea
n 
(SD) 
KY
N 
mea
n 
(SD) 
K/T 
ratio 
mean 
(SD) 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
e
s 
i
n 
K
Y
N
, 
K
/
T 
r
a
t
i
o 
Reini
nghau
s 
2014 
78  
 
46
.9 
(1
4.
2) 
156  
35
.2 
(1
1.
6) 
  NR 
3.1 + 
0.9 
52.8 
(12.9) 
 
 
 
 
 
 
NR 
 
NR 
2.6 + 
0.7 
45.23 
+ 
11.26 
 
 
 
 
 
 
NR 
 
 
Euthymic 
patients 
 
Increased 
KYN and 
KYN/TR
Y in 
patients  
 
Overweig
ht 
euthymic 
patients 
with BD 
had a 
significant
ly 
increased 
serum 
kynurenin
e 
concentrat
ion and 
KYN/TR
Y 
 
 
Neopte
rin 
levels 
were 
decreas
ed in 
patient
s with 
BD 
when 
compar
ed to 
healthy 
control
s 
 
Savitz
, 
2015a 
 
 
 
63  
(13
/50
) 
 
 
38
.8 
(1.
4) 
48  
(19
/29
) 
32
.6 
(1.
5) 
 
57.7 
(1.3) 
M 
 
1.90 
(0.1) 
nM 
0.03 
(0.001
) 
 
 
 
0.12 
(0.01) 
64.4 
(2.9) 
1.99 
(0.07
) 
0.03 
(0.001
) 
 
 
 
0.14 
(0.01) 
 
Bipolar 
depressed 
 
Decreased 
KynA/QA 
in patients 
CRP 
levels 
was not 
signific
antly 
differe
nt 
among 
AC
CE
PT
ED
 M
AN
US
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Auth
or, 
Year 
Bipolar 
patients 
Controls Bipolar patients Control patients 
Main 
findings 
Inflam
mator
y 
maker
s 
N 
(M
/F) 
Ag
e 
m
ea
n 
(S
D) 
N 
Ag
e 
m
ea
n 
(S
D) 
TRP 
mea
n 
(SD) 
KY
N 
mea
n 
(SD) 
K/T 
ratio 
mean 
(SD) 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
TRP 
mea
n 
(SD) 
KY
N 
mea
n 
(SD) 
K/T 
ratio 
mean 
(SD) 
KYN
A/Q
A 
Ratio 
mean 
(SD) 
the 
groups. 
Polett
i 
2016 
22  
(8/
14) 
 
46
.5 
(1
3.
7) 
14 
(6/
8) 
27
.2 
(8.
3) 
11.9
7  
(2.6) 
367.
82 
(112.
1) 
31.17 
(8.5) 
 
 
 
NR 
14.0
8 
(1.9) 
430.
54 
(148.
2) 
30.33 
(7.6) 
 
 
 
NR 
 
 
Bipolar 
depressed 
 
Decreased 
TRY, 
KYN and 
KYNA 
levels in 
patients 
 
No 
difference
s in K/T 
ratio 
NR 
Platze
r 
2017 
68 
(42
/26
) 
43
.6 
(1
4.
3) 
93 
(36
/57
) 
38
.1 
(1
5.
1) 
1173
9.07 
(271
4.62
) 
ng/
ml 
 
477.
29 
(230.
32) 
ng/m
l 
 NR 
 
 
 
NR 
1280
5.84 
(944
4.7) 
ng/m
l 
445.
49 
(152.
15) 
ng/m
l 
 
 NR 
 
 
 
 
NR 
 
Euthymic 
patients 
 
No 
significant 
difference 
in KYN 
and TRY 
in patients 
vs 
controls 
 
Increased 
KYN in 
males 
compared 
to females 
in both 
groups 
No 
correlat
ions 
was 
found  
betwee
n 
patient
s and 
inflam
matory 
marker
s  
NR- Not Reported; NS – Non significant 
 
TRP - Tryptophan; KYN - Kynurenine; K/T ratio – Kynurenine/Tryptophan ratio; KYNA - Kynurenic Acid; QA - Quinolinic 
acid 
 
MDD – Major Depressive Disorder; BD  - Bipolar Disorder; Pts – patients; HC - Healthy Controls 
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